MedPath

Effects of pioglitazone on bone formation and resorption markers in type 2 diabetes mellitus.

Not Applicable
Conditions
type 2 diabetes mellitus.
Registration Number
JPRN-UMIN000023805
Lead Sponsor
niversity of Occupational and Environmental Health, Japan
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

Patients treated with pioglitazone, metformin or insulin, with type 1 diabetes, history of secondary osteoporosis, heart failure, renal failure, liver failure, and patients receiving any drugs that affect bone metabolism (bisphosphonates, vitamin K, estrogen, calcium, anabolic steroids, or male and female hormones) were excluded from the research.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath